



HAL
open science

Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View

F. Lemaître, C. Tron, M. Rayar

► **To cite this version:**

F. Lemaître, C. Tron, M. Rayar. Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View. *American Journal of Transplantation*, 2017, 17 (6), pp.1691-1692. 10.1111/ajt.14237 . hal-01558820

HAL Id: hal-01558820

<https://univ-rennes.hal.science/hal-01558820>

Submitted on 12 Jul 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DR. MICHEL RAYAR (Orcid ID : 0000-0003-3113-2260)

Received Date : 02-Feb-2017

Revised Date : 08-Feb-2017

Accepted Date : 11-Feb-2017

Article type : L - Letter to the Editor

FLUCTUATION DOES NOT MEAN VARIABILITY: A PHARMACOKINETIC POINT-OF-VIEW

Florian Lemaitre^{1,2,3}, Camille Tron^{1,2,3}, Michel Rayar^{2,3,4}

¹ Service de Pharmacologie Clinique et épidémiologique, Centre hospitalier Universitaire Pontchaillou, Rennes, France

² INSERM, CIC1414, Rennes, France

³ Faculté de médecine, Université Rennes 1, Rennes, France

⁴ Service de chirurgie hépatobiliaire et digestive, Centre hospitalier Universitaire Pontchaillou, Rennes, France

Corresponding author: Florian Lemaitre; florian.lemaitre@chu-rennes.fr

Dear editor,

We read with interest the article by Tremblay *et al.* (1) recently published in the American Journal of Transplantation and wanted to congratulate them for their study.

The authors reported a randomized, cross-over study comparing different formulations of tacrolimus (TAC) (immediate release (IR), extended release (ER) and the recently labelled once-daily tacrolimus formulation (LCPT)) in stable renal transplant recipients. Patients treated with IR-TAC were converted to ER-TAC with a dosage conversion factor of 1:1 on a mg basis or to LCPT with a dosage conversion factor of 1:0.8. As expected, the 1:0.8 conversion factor to LCPT resulted in higher TAC exposure. Indeed, in a phase II study, Osama Gaber *et al.* (2) have already explored the relationship between daily dose of TAC and exposure in 60 stable renal transplant recipients converted to LCPT and

concluded that, compared to IR-TAC dosage, a 30% dose reduction of LCPT produced similar areas under the curve (AUCs). Tremblay *et al.* strengthened this finding reinforcing the message for clinicians aiming at converting patients to LCPT.

The authors also found that LCPT is associated with less fluctuation between maximum (“peak”) exposure and trough concentration with a lower peak exposure level than the other forms. However, this reduced fluctuation should not be misunderstood with a decrease of inpatient nor interpatient variability. Indeed, fluctuation is defined as the ratio of the peak concentration (C_{max}) minus trough concentration (C_{min}) over the average concentration (C_{av}) (i.e. (C_{max} – C_{min})/C_{av}) expressed as a percentage, while the variability (i.e the coefficient of variation (CV)), is defined by the ratio between the standard deviation of TAC C_{min} over the mean value of measured TAC, in the same patient for inpatient variability or between patients for interpatient variability (3).

As LCPT is a delayed absorption formulation with a progressive resorption throughout the digestive tract, its C_{max} is lower than immediate release formulation, when normalized to the AUC, while C_{min} is approximately similar. Therefore, the value of C_{max}-C_{min} is lower with LCPT, while the C_{av}, which is dependent on AUC and time dosage interval (τ) (i.e. C_{av} = AUC/τ) is roughly similar between the different formulations when AUC is normalized. This implies that the fluctuation is necessarily lower with LCPT when compared to the IR-TAC or ER-TAC.

However, to date, the high fluctuation has no clinical relevance while high inpatient variability could be a potential biomarker predictive of outcome (i.e. increase incidence of acute rejection, graft loss, apparition of *de novo* donor specific antibodies) (3-5). The interpatient variability (frequently expressed as the between-patient CV of AUCs) is also relevant as it describes the variability of drug exposure from one patient to another. Interestingly, in the study of Tremblay *et al.*, even if the population size is low, the CV of AUC tended to be higher for LCPT.

In conclusion, variability and fluctuation are two distinct parameters with a potential clinical relevance only for the first one. These terms should not be confused with one other and clinicians should be aware of this difference.

Disclosure

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. FL received a research grant from Astellas SA. The other authors have no conflicts of interest to disclose.

References

1. Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (Tacrolimus) Formulations (ASTCOFF): An open-label, prospective, randomized, two-arm, three-period crossover study. *Am J Transplant* 2017; 17: 432–442.

2. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): A phase 2 trial of stable renal transplant recipients. *Transplantation* 2013; 96: 191–197.
3. Borra LC, Roodnat JJ, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. *Nephrol Dial Transplant* 2010; 25: 2757–2763.
4. Rodrigo E, Segundo DS, Fernandez-Fresnedo G, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. *Transplantation* 2016; 100: 2479–2485.
5. Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DR. High inpatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. *Am J Transplant* 2016; doi: 10.1111/ajt.